DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market
DermTech’s Test Included in Expert Panel’s Clinical Management Recommendations for Cutaneous Melanoma
DermTech Announces Successful Closing of Business Combination with Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. to Merge with DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis
Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis
DermTech Announces the Publication of a Health Economic and Utility Study of the PLA in JAMA Dermatology
DermTech Announces Publication of “Gene Expression Analysis Differentiates Melanomas from Spitz Nevi”
DermTech’s Late Breaking Abstract Presented at AAD Validates Gene Expression Against High Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma
DermTech’s Collaborators Present Research Studies at AAD Supporting the Use of “Adhesive Patch Skin Biopsy” in Cutaneous Basal Cell and Squamous CellCarcinoma
DermTech Announces Preferred Provider Agreements with TriCare and ACPN and Credentialing by UnitedHealthcare
DermTech Announces Basal Cell Carcinoma Study Expanding Clinical Applications for Platform Technology
For Immediate Release DermTech Publishes Clinical Data in the Journal of American Academy of Dermatology San Diego, July 14, 2014 (BUSINESS WIRE) – DermTech International (“DermTech”), a privately held molecular diagnostics company commercializing non-invasive...
DermTech Selected as a Finalist for CONNECT’s 28th Annual Most Innovative New Product Awards Life Science Diagnostics & Research Tools
SAN DIEGO (SEPTEMBER 30, 2015) – Today, DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announced that its Pigmented Lesion Assay has been selected as a finalist in CONNECT’s Most...
San Diego, March 19, 2015 (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces that it has been issued a notice of allowance by the U.S. Patent Office for...
San Diego, March 19, 2015 (BUSINESS WIRE) – DermTech, Inc., a privately held dermatology company commercializing non-invasive gene expression tests for skin cancer, announces the presentation of a poster at the 2015 American Academy of Dermatology’s Annual...